Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Aurora Cannabis Inc Market Cap
The Aurora Cannabis Inc (ACB) share price is expected to increase by 340.44% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ACB. Price targets range from $23.65162 at the low end to $23.65162 at the high end. The current analyst consensus for ACB is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Aurora Cannabis Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Aurora Cannabis Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ACB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Pablo Zuanic Zuanic & Associates | Neutral | Initiates | Jun 27, 2024 | |
| John Zamparo CIBC | Neutral | $1 | Maintains | Jun 16, 2023 |
| Matt Bottomley Canaccord Genuity | Hold | $0.8 | Maintains | Jun 15, 2023 |
| John Zamparo CIBC | Neutral | $1.75 | Maintains | Feb 13, 2023 |
| Michael Lavery Piper Sandler | Neutral | $3 | Maintains | Sep 21, 2022 |
| Bill Kirk MKM Partners | Neutral | Upgrade | Sep 28, 2021 | |
| Tamy Chen BMO Capital | Underperform | $9 | Downgrade | Dec 18, 2020 |
Cowen & Co. | Outperform | Initiates | Nov 25, 2020 | |
Bank of America | Neutral | Downgrade | Nov 25, 2020 | |
B of A Securities | Neutral | Downgrade | Nov 25, 2020 | |
Stifel | Sell | Downgrade | Nov 25, 2020 | |
Needham | Hold | Initiates | Nov 25, 2020 | |
Piper Sandler | Neutral | Maintains | Nov 25, 2020 | |
Jefferies | Buy | Initiates | Nov 25, 2020 | |
Stifel Nicolaus | Hold | Initiates | Nov 25, 2020 | |
MKM Partners | Sell | Initiates | Nov 25, 2020 | |
Seaport Global | Neutral | Initiates | Nov 25, 2020 | |
Piper Jaffray | Neutral | Maintains | Nov 25, 2020 | |
Ladenburg Thalmann | Neutral | Downgrade | Nov 25, 2020 | |
Desjardins | Buy | Initiates | Nov 25, 2020 |
When did it IPO
2014
Staff Count
1,073
Country
Canada
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Mr. Miguel Martin
Market Cap
$295.2M
In 2023, ACB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) announced a leadership transition with CEO Miguel Martin becoming Executive Chairman and Ron Funk appointed Lead Independent Director.
Why It Matters - Leadership changes can signal strategic shifts and affect company direction. Investors may evaluate how these roles impact Aurora Cannabis's growth and governance.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Aurora Cannabis Inc. is advancing auto-flowering technology, potentially transforming cannabis cultivation in high-latitude areas and enhancing breeding strategies.
Why It Matters - Aurora Cannabis's advancements in auto-flowering technology could enhance yield and efficiency in high-latitude cannabis cultivation, potentially boosting revenues and market competitiveness.
Thu, 19 Sep 2024
Sentiment - POSITIVE
Source - MarijuanaStocks
Summary - Canadian cannabis companies are expanding into the U.S. market, which is projected to reach $45 billion in sales by 2025 due to increasing legalization efforts. Investors are monitoring this development.
Why It Matters - The Canadian cannabis market's expansion into the U.S. presents growth opportunities. U.S. sales projections and increasing legalization trends may boost Canadian company valuations.
Mon, 09 Sep 2024
Sentiment - POSITIVE
Source - Market Watch
Summary - Donald Trump backs the Biden administration's proposal to classify cannabis as Schedule III, indicating potential regulatory changes in the cannabis industry.
Why It Matters - Trump's support for Schedule III cannabis classification could signal regulatory changes, potentially boosting cannabis stocks and attracting institutional investors in the sector.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Vectura Fertin Pharma launched its first medical cannabis CBD lozenge in Canada through a collaboration with Aurora Cannabis to leverage their patient platform for future products.
Why It Matters - The launch of Vectura's CBD lozenge and collaboration with Aurora expands product offerings in the growing medical cannabis market, potentially boosting revenue and market share for both companies.
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - 24/7 Wall Street
Summary - A Kamala Harris win in the 2024 presidential election may positively impact stocks across multiple sectors, according to 24/7 Wall St. Insights.
Why It Matters - A Kamala Harris victory could signal policy shifts favoring certain sectors, potentially leading to stock market gains and influencing investment strategies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
